Macro Tsimmis

intelligently hedged investment

Vertex (VRTX) update #20

Posted by intelledgement on Mon, 03 Nov 08

Shares of VRTX, our development-stage biotech company, popped up as much as 5% today in the wake of the presentation of new data over the weekend at the biannual American Association for the Study of Liver Diseases meeting in San Francisco. The data—from the company’s unusually large phase 2 trials which have recently been completed—confirmed the efficacy of telaprevir in treating hepatitis C patients who had previously failed to be cured by the current standard of care treatment (48 weeks of interferon plus ribaviron).

Also, there were more data indicating that a twice-a-day regimen of telaprevir may suffice, from interim results of another ongoing phase 2 trial.

For more details on all the results, check out the press release from Saturday. And for a good summary of where telaprevir stands in relation to the competition—primarly, Schering-Plough’s boceprevir—see Adam Feuerstein’s report from the AASLD posted early today.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: